GLUCOTRACK INC (GCTK)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$2.98-10.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · GCTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 870.8% |
| Our one-year growth estimate | diamond | -29.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 899.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of — · Company calendar date is not available
GCTK — private placement
Dated 2026-08-05
Entry Into a Material Definitive Agreement. On August 4, 2026, Glucotrack, Inc. (the “Company”) entered into a series of definitive agreements providing for (i) a follow-on investment in the Company’s existing bridge financing (the “Bridge Follow-On”) and (ii) an interim private placement (the “Interim PIPE” and, together with the Bridge Follow-On, the “Follow-On Financing”). This section describes the material provisions of the Follow-On Financing but does not purport to describe all of the…
Why it matters: The reverse stock split aims to maintain Nasdaq listing. It impacts stock liquidity and investor perception.
Watch forReverse stock split takes effect on August 31, 2026, with compliance maintained.
Also watch forStock fails to maintain a closing bid price of at least $1.00 after the split.
Why it matters: The company is at risk of delisting. Staying compliant is crucial for its future.
Worry ifA public announcement that shows compliance with Nasdaq listing rules.
Less concerning ifMore notices of non-compliance from Nasdaq or a decision to delist.
Why it matters: The company has struggled with negative cash flow. Improvement signals better financial health.
Supportive ifCash flow from operations turns positive in the next quarterly report.
Worry ifCash flow from operations is still negative or gets worse.
Why it matters: FDA approval is crucial for starting U.S. clinical trials of the implantable glucose monitor.
Supportive ifFDA grants approval for the IDE application to begin the clinical study.
Worry ifThe FDA denies the IDE application or asks for more data.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$556 on $10,000 · ±5.6% | How much price usually moves either way. |
| Bad day | $1,480 loss on $10,000 · 14.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,812 loss on $10,000 · 98.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Better cash flow shows stronger financial health and good management.
Supportive ifCash from operations is trending positive or is less negative than -$4M.
Worry ifCash from operations stays negative or gets worse in the next earnings report.
Why it matters: New studies can prove the technology. They can also build trust with investors and regulators.
Supportive ifAt least one new peer-reviewed study published by the end of 2026.
Worry ifNo new peer-reviewed studies are published by the end of 2026.
Why it matters: Following Nasdaq rules helps keep the company's stock listing.
Worry ifThe company gets confirmation that it meets Nasdaq's minimum bid price rule.
Less concerning ifThe company gets more notices of non-compliance from Nasdaq.
Why it matters: Starting the trial is key for GCTK's growth plans and could attract investor interest.
Supportive ifAnnouncement of the trial start date or the first patient enrolled in the U.S. clinical trial.
Worry ifTrial start is delayed due to funding or operational problems.
Why it matters: Updates on LT-100 may show progress in treatment.
Supportive ifLōkahi begins clinical tests for LT-100 as a single injection.
Worry ifThere are no updates or delays for LT-100's clinical evaluation.
Why it matters: More studies can build trust and support for the CBGM technology.
Supportive ifThe company shares new studies that support the CBGM technology.
Worry ifNo new peer-reviewed studies are published within the next six months.
Why it matters: The FDA's choice will affect when clinical studies for the glucose monitor start.
Supportive ifFDA approval of the IDE application to initiate U.S. clinical studies for the CBGM.
Worry ifFDA denies the IDE application or asks for a lot more data.
Why it matters: Starting the clinical study is key. It helps prove the CBGM technology and attract investors.
Supportive ifAnnouncement of the start date for the U.S. clinical study of the CBGM technology.
Worry ifDelay in starting the clinical study beyond the second half of 2026.
Why it matters: Staying compliant is vital for Glucotrack's trading on Nasdaq and for investor trust.
Worry ifStock maintains a closing bid price of at least $1.00 for each trading day through November 9, 2026.
Less concerning ifStock price falls below $1.00 for an extended period, risking delisting from Nasdaq.